Press Release
-
Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US2021-05-28Baltimore, May26,2021 /--PrositSole Biotechnology,aclinical-stagebiotechcompanydevelopingnovelprotein therapeutics,todayannouncesthatithasinitiatedthefirst-in-human(“
-
PSP001 received Safe-to-proceed Letter by FDA2021-02-05On 3rd Feb. 2021, FDA issued Safe-to-Proceed letter to investigational new drug application (IND) of PSP001.
-
PSP001 (PEGIL29 Chimera) IND submission (FDA)2021-02-05On 7th Jan 2021 US time (8th Jan 2021, Beijing Time), Prosit Sole Submitted PSP001 (PEGIL29 Chimera) IND to FDA. Appreciated for great effort of Prosit sole's team members.
-
Dr. Hongyu Liu, CEO of Prosit Sole Biotechnology (Beijing) attended the Hong Kong Summit of Winner of Nobel Prize and Turing Award at International Center of Innovative Technology, as a leader of inno2019-08-05Dr. Hongyu Liu, a veteran of the pharmaceutical industry and founder/CEO of an orphan drug company (Prosit Sole Biotechnology (Beijing)), attended the Hong Kong Summit of Winner of Nobel Prize and Turing Award at International Center of Innovative Technol
-
Dr. Hongyu Liu, Founder and CEO of Prosit Sole Biotechnology (Beijing), as an invited speaker, attended the 4th Annual Meeting of Founders Club for Innovative Medicines.2019-08-05Dr. Hongyu Liu, a leader in the discovery and development of innovative orphan drugs in China and globally, conducted a presentation at the 4th Annual Meeting of Founders Club for Innovative Medicines. In his speech, Dr. Liu discussed the market opportuni
-
May 2019, Prosit Sole entered into a Partnership with CDDG Group, WA, USA2019-08-05May 11. 2019, Beijing, PR China and Seattle, WA, USA----Prosit Sole Biotechnology (Beijing, China) and Cascadian Drug Development Group (CDDG, Seattle, WA) signed a formal agreement to form a drug development partnership in advancing PSP001 into the clini